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Background: We investigated the dose dependent effects of N-3 polyunsaturated fatty acid (PUFA) on insulin resistance and inflammatory markers 
in patients with metabolic syndrome (MS).
Methods: Subjects with MS were randomly enrolled in placebo and N-3 PUFA groups. The N-3 PUFA group received 2 g for 6 weeks, and switched 4 
g for another 6 weeks. We measured lipid profiles, inflammatory markers and profiles of insulin resistance at each period.
Results: Fifty-three (26 of N-3 PUFA and 27 of placebo) subjects completed this study.
High sensitivity C-reactive protein (hs-CRP) were significantly lower in 2g of N-3 PUFA at 6 weeks (0.13 ± 0.03 vs. 0.29 ± 0.05 mg/L, p = 0.02) and 
4g of N-3 PUFA at 12 weeks (0.11 ± 0.01 vs. 0.27 ± 0.05 mg/L, p = 0.01) than placebo. However, there was no significant difference for hs-CRP 
levels between 2g and 4g of N-3 PUFA (0.13 ± 0.03 vs. 0.11 ± 0.01 mg/L, p = 0.33). Homeostasis model assessment of insulin resistance (HOMA-
IR) was significantly lower in 4g of N-3 PUFA at 12 weeks (2.76 ± 0.32 vs. 4.94 ± 0.82, p = 0.03) than placebo. Also, there was significant difference 
of HOMA-IR between 2g and 4g of N-3 PUFA (3.37 ± 0.26 vs. 2.76 ± 0.32, p = 0.01).
Conclusion: N-3 PUFA administration ameliorates insulin resistance with dose-dependent manner and systemic inflammation marker without dose 
dependency in patients with MS.
